PT2691155T - Preparação de conjugados de anticorpo de maitansinoide por processo de uma etapa - Google Patents
Preparação de conjugados de anticorpo de maitansinoide por processo de uma etapaInfo
- Publication number
- PT2691155T PT2691155T PT12714160T PT12714160T PT2691155T PT 2691155 T PT2691155 T PT 2691155T PT 12714160 T PT12714160 T PT 12714160T PT 12714160 T PT12714160 T PT 12714160T PT 2691155 T PT2691155 T PT 2691155T
- Authority
- PT
- Portugal
- Prior art keywords
- preparation
- step process
- antibody conjugates
- maytansinoid antibody
- maytansinoid
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Analytical Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161468997P | 2011-03-29 | 2011-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2691155T true PT2691155T (pt) | 2019-02-19 |
Family
ID=46928080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT12714160T PT2691155T (pt) | 2011-03-29 | 2012-03-29 | Preparação de conjugados de anticorpo de maitansinoide por processo de uma etapa |
Country Status (25)
Country | Link |
---|---|
US (7) | US8795673B2 (pt) |
EP (2) | EP3545977A1 (pt) |
JP (5) | JP6000329B2 (pt) |
KR (6) | KR102103302B1 (pt) |
CN (2) | CN103717262B (pt) |
AU (5) | AU2012236398B2 (pt) |
CA (1) | CA2831467C (pt) |
CY (1) | CY1121321T1 (pt) |
DK (1) | DK2691155T3 (pt) |
EA (2) | EA033468B1 (pt) |
ES (1) | ES2709577T3 (pt) |
HR (1) | HRP20190243T1 (pt) |
HU (1) | HUE041384T2 (pt) |
IL (3) | IL228559A (pt) |
LT (1) | LT2691155T (pt) |
ME (1) | ME03353B (pt) |
MX (2) | MX369659B (pt) |
NZ (1) | NZ726386A (pt) |
PL (1) | PL2691155T3 (pt) |
PT (1) | PT2691155T (pt) |
RS (1) | RS58367B1 (pt) |
SI (1) | SI2691155T1 (pt) |
TR (1) | TR201902180T4 (pt) |
UA (1) | UA116524C2 (pt) |
ZA (1) | ZA201605918B (pt) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
EP2399609B1 (en) | 2005-08-24 | 2015-03-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
NZ599239A (en) | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
HUE043645T2 (hu) | 2009-06-03 | 2019-08-28 | Immunogen Inc | Konjugációs módszerek |
SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
AR080513A1 (es) | 2010-03-12 | 2012-04-11 | Inmunogen Inc | Moleculas de union cd37 y sus inmunoconjugados |
PT2691155T (pt) | 2011-03-29 | 2019-02-19 | Immunogen Inc | Preparação de conjugados de anticorpo de maitansinoide por processo de uma etapa |
EP2694106B1 (en) * | 2011-04-01 | 2017-12-13 | ImmunoGen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
BR112015004229B1 (pt) | 2012-08-31 | 2023-02-07 | Immunogen, Inc | Anticorpos ou fragmentos de ligação ao antígeno do mesmo que se liga especificamente à proteína folr1, kit de imunoensaio, método de detecção in vitro de proteína folr1, uso de um agente ativo, e método para monitoramento da eficácia terapêutica |
CA2886993A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
US20150306242A1 (en) * | 2012-10-04 | 2015-10-29 | Immunogen, Inc. | Process for preparing stable antibody maytansinoid conjugates |
WO2014055893A1 (en) * | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates |
SG11201502896XA (en) | 2012-10-16 | 2015-05-28 | Endocyte Inc | Drug delivery conjugates containing unnatural amino acids and methods for using |
US8769557B1 (en) | 2012-12-27 | 2014-07-01 | The Nielsen Company (Us), Llc | Methods and apparatus to determine engagement levels of audience members |
JP6494533B2 (ja) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
US9901647B2 (en) | 2013-02-28 | 2018-02-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
AP2015008656A0 (en) | 2013-03-15 | 2015-08-31 | Novartis Ag | Antibody drug conjugates |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
SI3038650T1 (sl) | 2013-08-30 | 2021-11-30 | Immunogen, Inc. | Protitelesa in preiskave za odkrivanje folatnega receptorja 1 |
TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
CA2940685C (en) | 2014-03-11 | 2023-10-24 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antibodies and uses thereof |
EP3682904A1 (en) | 2014-06-30 | 2020-07-22 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
EP3180360A1 (en) | 2014-08-12 | 2017-06-21 | Novartis AG | Anti-cdh6 antibody drug conjugates |
EP3223857A4 (en) * | 2014-10-31 | 2018-06-27 | Formation Biologics Inc. | Egfr antibody-based combination therapy |
CN106267225B (zh) * | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
TW201711702A (zh) | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法 |
MA44391A (fr) | 2015-06-08 | 2019-01-23 | Debiopharm Int Sa | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
EP3341414A4 (en) * | 2015-08-28 | 2019-03-27 | Debiopharm International SA | ANTIBODIES AND ASSAYS FOR DETECTION OF CD37 |
JP6880006B2 (ja) | 2015-09-17 | 2021-06-02 | イミュノジェン, インコーポレイテッド | 抗folr1免疫複合体を含む治療組み合わせ |
JP2019501139A (ja) | 2015-11-25 | 2019-01-17 | イミュノジェン・インコーポレーテッド | 医薬製剤及びその使用 |
CN108601848A (zh) * | 2016-02-05 | 2018-09-28 | 伊缪诺金公司 | 用于制备细胞结合剂-细胞毒性剂缀合物的有效方法 |
CN108421048B (zh) * | 2016-09-28 | 2021-04-20 | 首都医科大学附属北京世纪坛医院 | 纳米活性碳靶向药物递送系统、制备方法及其用途 |
WO2018083633A1 (en) | 2016-11-02 | 2018-05-11 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
CN116785451A (zh) * | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
CN111867621A (zh) * | 2018-01-18 | 2020-10-30 | 美真达治疗公司 | 用于耗尽cd134+细胞的组合物和方法 |
EP3552631A1 (en) | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
CN111620927B (zh) * | 2019-05-20 | 2022-11-11 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物中间体的一锅法制备工艺 |
AU2020307561A1 (en) * | 2019-06-25 | 2022-01-20 | Tva (Abc), Llc | SSTR-targeted conjugates and formulations thereof |
KR20220051332A (ko) | 2019-07-10 | 2022-04-26 | 싸이브렉사 3, 인크. | 치료제로서의 미세소관 표적화제의 펩티드 접합체 |
TW202116778A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩二號公司 | 作為治療劑之細胞毒素之肽結合物 |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1043543A (en) | 1912-02-15 | 1912-11-05 | Robert H Shaw | Poultry-house door. |
SE430062B (sv) | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
US4137230A (en) * | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4664911A (en) | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
DE3587294T2 (de) | 1985-01-22 | 1993-09-30 | Saint Gobain Vitrage | Verfahren zur Herstellung einer dünnen Metalloxidbeschichtung auf einem Substrat, insbesondere Glas und deren Verwendung als Verglasung. |
GB8600582D0 (en) | 1986-01-10 | 1986-02-19 | Ca Minister Nat Defence | Purifying biological materials |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4859449A (en) | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
US5241078A (en) | 1988-06-14 | 1993-08-31 | Cetus Oncology | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5024834A (en) | 1988-07-12 | 1991-06-18 | Cetus Corporation | Thioether linked immunotoxin conjugates |
CA2006408A1 (en) | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5714149A (en) | 1989-02-10 | 1998-02-03 | Celltech Therapeutics Limited | Crosslinked antibodies and processes for their preparation |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
US5137877B1 (en) | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
CA2048078A1 (en) * | 1990-11-15 | 1992-05-16 | Wolfgang A. Wrasidlo | Chemical modification of antibodies for creation of immunoconjugates |
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
SE470006B (sv) * | 1991-09-26 | 1993-10-25 | Corline Systems Ab | Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5556623A (en) * | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
IL111748A0 (en) | 1993-12-03 | 1995-01-24 | Zeneca Ltd | Proteins |
US5580853A (en) | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US5747446A (en) | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US5919758A (en) | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
US5612474A (en) | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
WO1996039183A1 (en) * | 1995-05-31 | 1996-12-12 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector molecules |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5958872A (en) | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
WO1998026747A2 (en) | 1996-12-17 | 1998-06-25 | Terman David S | Superantigen based methods and compositions for treatment of diseases |
US6462070B1 (en) * | 1997-03-06 | 2002-10-08 | The General Hospital Corporation | Photosensitizer conjugates for pathogen targeting |
US6371975B2 (en) * | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
ES2231991T3 (es) * | 1997-06-11 | 2005-05-16 | Borean Pharma A/S | Modulo de trimerizacion. |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US5958677A (en) | 1997-07-28 | 1999-09-28 | The New York Blood Center, Inc. | Method for purifying viral nucleic acids |
EP1005569A2 (en) | 1997-08-01 | 2000-06-07 | MorphoSys AG | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
US5965714A (en) | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
ATE296105T1 (de) * | 1997-10-03 | 2005-06-15 | Galenica Pharmaceuticals Inc | Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel |
US6121236A (en) * | 1998-03-24 | 2000-09-19 | The Children's Medical Center Corporation | Multivalent ligands which modulate angiogenesis |
JP2002513028A (ja) * | 1998-04-28 | 2002-05-08 | ガレニカ ファーマシューティカルズ, インコーポレイテッド | ポリサッカリド抗原結合体 |
US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
ES2188202T3 (es) | 1998-07-13 | 2003-06-16 | Univ Texas | Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos. |
TW593241B (en) | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
EP1229934B1 (en) | 1999-10-01 | 2014-03-05 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
DE60032633T2 (de) | 1999-11-24 | 2007-10-04 | Immunogen Inc., Cambridge | Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung |
DK1242438T3 (da) | 1999-12-29 | 2007-02-12 | Immunogen Inc | Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse |
CA2398136A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US20060062786A1 (en) | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
MX337162B (es) | 2001-01-05 | 2016-02-15 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina. |
EA007388B1 (ru) | 2001-01-29 | 2006-10-27 | Идек Фармасьютикалз Корпорейшн | Модифицированные антитела и способы применения |
JP2005507857A (ja) * | 2001-02-07 | 2005-03-24 | ベズ イズレイル ディーコネス メディカル センター | 改変psmaリガンド及びそれに関する利用 |
US20020197261A1 (en) | 2001-04-26 | 2002-12-26 | Chun Li | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use |
EP1392361A4 (en) | 2001-05-11 | 2009-08-05 | Univ Texas | THERAPY BASED ON ANTI-CD26 MONOCLONAL ANTIBODIES AGAINST DISORDERS ASSOCIATED WITH CELLS EXPRESSING CD26 |
EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
EP1392360B1 (en) | 2001-06-01 | 2011-11-30 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
TW593239B (en) | 2001-06-04 | 2004-06-21 | Kevin Dale Allen | One-step production of 1,3-propanediol from ethylene oxide and syngas with a catalyst with a phospholanoalkane ligand |
DE60230670D1 (de) | 2001-12-11 | 2009-02-12 | Merck & Co Inc | Staphylococcus aureus exopolysaccharid und verfahren |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
WO2003057163A2 (en) | 2002-01-03 | 2003-07-17 | Smithkline Beecham Corporation | Methods for preparing immunoconjugates |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7591994B2 (en) * | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US6534660B1 (en) | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
US7323553B2 (en) | 2002-04-26 | 2008-01-29 | Genentech, Inc. | Non-affinity purification of proteins |
DK2371392T3 (en) | 2002-05-02 | 2015-08-31 | Wyeth Holdings Llc | Calicheamicin derivative / carrier conjugates |
US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
AU2003251592A1 (en) | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
ATE499116T1 (de) | 2002-08-16 | 2011-03-15 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
US7538092B2 (en) * | 2002-10-08 | 2009-05-26 | Fresenius Kabi Deutschland Gmbh | Pharmaceutically active oligosaccharide conjugates |
HUE033651T2 (en) * | 2002-10-30 | 2017-12-28 | Nuevolution As | A method for producing two-function complexes |
MXPA05004712A (es) | 2002-11-07 | 2005-11-23 | Immunogen Inc | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos. |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
CA2737127C (en) | 2003-05-14 | 2016-07-26 | Immunogen, Inc. | Maytansinoid-antibody conjugate compositions |
ES2559670T3 (es) | 2003-05-20 | 2016-02-15 | Immunogen, Inc. | Agentes citotóxicos mejorados que comprenden nuevos maitansinoides |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
KR20140033239A (ko) | 2003-06-27 | 2014-03-17 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
WO2005002597A1 (en) * | 2003-07-02 | 2005-01-13 | Polycord, Inc. | Method for delivering polymerized therapeutic agent compositions and compositions thereof |
CA2542886A1 (en) * | 2003-11-05 | 2005-05-19 | Neelima M. Bhat | Enhanced b cell cytotoxicity of cdim binding antibody |
US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
US20110064754A1 (en) | 2005-03-03 | 2011-03-17 | Center For Molecular Medicine And Immunology | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
EP1610818A4 (en) | 2004-03-03 | 2007-09-19 | Millennium Pharm Inc | MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF |
WO2005115477A2 (en) | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
US20060073528A1 (en) * | 2004-05-14 | 2006-04-06 | Jean-Michel Lecerf | Measurement methods |
MXPA06013413A (es) | 2004-05-19 | 2007-01-23 | Medarex Inc | Enlazadores quimicos y conjugados de los mismos. |
RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
AU2004224925C1 (en) | 2004-08-30 | 2011-07-21 | Biotest Ag | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
AR052774A1 (es) | 2004-10-08 | 2007-04-04 | Wyeth Corp | Inmunoterapia para trastornos autoinmunes |
CA2587589A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
AU2005314392B2 (en) | 2004-12-09 | 2011-04-14 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
US7408030B2 (en) | 2005-01-13 | 2008-08-05 | North Carolina State University | Purification of immunoglobulins using affinity chromatography and peptide ligands |
AU2006213662B2 (en) | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
WO2006096653A2 (en) | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
WO2006113623A2 (en) | 2005-04-15 | 2006-10-26 | Immunogen, Inc. | Elimination of heterogeneous or mixed cell population in tumors |
GB2427360A (en) * | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
ES2424242T3 (es) | 2005-07-15 | 2013-09-30 | Angiochem Inc. | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
EA014513B1 (ru) * | 2005-08-03 | 2010-12-30 | Иммьюноджен, Инк. | Композиция иммуноконъюгата |
US20070134724A1 (en) * | 2005-08-04 | 2007-06-14 | Peter Davies | Phosphorylation of tau by abl |
EP2399609B1 (en) | 2005-08-24 | 2015-03-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
AU2006293426A1 (en) * | 2005-09-22 | 2007-03-29 | Hadasit Medical Research Services & Development Limited | Dextran and arabinogalactan conjugates of therapeutically active compounds |
JP5290756B2 (ja) | 2005-09-26 | 2013-09-18 | メダレックス インコーポレイテッド | 抗体−薬剤コンジュゲート及びその使用 |
US7928113B2 (en) | 2005-11-14 | 2011-04-19 | University Of Southern California | Integrin-binding small molecules |
US7964415B2 (en) * | 2006-04-26 | 2011-06-21 | Cardiogenics Inc. | Stable water-soluble polyethylenimine conjugates and methods of use thereof |
SG172656A1 (en) | 2006-05-30 | 2011-07-28 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
KR101528939B1 (ko) | 2006-07-18 | 2015-06-15 | 사노피 | 암 치료를 위한 epha2에 대한 길항제 항체 |
US20080213349A1 (en) * | 2006-09-11 | 2008-09-04 | Deepak Ramesh Thakker | Liposome Complexes Containing Pharmaceutical Agents and Methods |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
PT2019104E (pt) | 2007-07-19 | 2013-12-03 | Sanofi Sa | Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica |
MY157165A (en) | 2008-04-30 | 2016-05-13 | Immunogen Inc | Cross-linkers and their uses |
EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
GB0811743D0 (en) * | 2008-06-26 | 2008-07-30 | Hemosol Biopharma Inc | Composition |
US20110223257A1 (en) * | 2008-11-17 | 2011-09-15 | Enzon Pharmaceuticals, Inc. | Releasable fusogenic lipids for nucleic acids delivery systems |
KR102021728B1 (ko) | 2009-02-05 | 2019-09-16 | 이뮤노젠 아이엔씨 | 신규한 벤조디아제핀 유도체 |
UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
HUE043645T2 (hu) | 2009-06-03 | 2019-08-28 | Immunogen Inc | Konjugációs módszerek |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
TW201117814A (en) | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
KR20110103182A (ko) | 2010-03-12 | 2011-09-20 | 삼성전자주식회사 | 입체 영상 표시 장치 |
AR080513A1 (es) | 2010-03-12 | 2012-04-11 | Inmunogen Inc | Moleculas de union cd37 y sus inmunoconjugados |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
US20120149732A1 (en) * | 2010-12-14 | 2012-06-14 | Alexander Chucholowski | Multifunctional linkers and methods for the use thereof |
WO2012112708A1 (en) * | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
PT2691155T (pt) * | 2011-03-29 | 2019-02-19 | Immunogen Inc | Preparação de conjugados de anticorpo de maitansinoide por processo de uma etapa |
WO2012135522A2 (en) | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Process for manufacturing conjugates of improved homogeneity |
CN103619357A (zh) | 2011-03-29 | 2014-03-05 | 伊缪诺金公司 | 用于制造具有改善的同质性的缀合物的方法 |
EP2694106B1 (en) | 2011-04-01 | 2017-12-13 | ImmunoGen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
US20130071482A1 (en) * | 2011-09-20 | 2013-03-21 | The University Of Kentucky Research Foundation | Block copolymer cross-linked nanoassemblies as modular delivery vehicles |
BR112014014464A2 (pt) | 2011-12-13 | 2017-06-13 | Immunogen Inc | uso de n-hidroxisuccinimida para melhorar a estabilidade do conjugado |
CA2886993A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
WO2014055893A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates |
US20150306242A1 (en) | 2012-10-04 | 2015-10-29 | Immunogen, Inc. | Process for preparing stable antibody maytansinoid conjugates |
US10253099B2 (en) * | 2012-12-05 | 2019-04-09 | Ruprecht-Karls-Universität Heidelberg | Conjugates of proteins and multivalent cell-penetrating peptides and their uses |
-
2012
- 2012-03-29 PT PT12714160T patent/PT2691155T/pt unknown
- 2012-03-29 AU AU2012236398A patent/AU2012236398B2/en active Active
- 2012-03-29 KR KR1020137028135A patent/KR102103302B1/ko active IP Right Grant
- 2012-03-29 DK DK12714160.4T patent/DK2691155T3/en active
- 2012-03-29 EA EA201391398A patent/EA033468B1/ru unknown
- 2012-03-29 TR TR2019/02180T patent/TR201902180T4/tr unknown
- 2012-03-29 KR KR1020217019701A patent/KR102351886B1/ko active IP Right Grant
- 2012-03-29 CA CA2831467A patent/CA2831467C/en active Active
- 2012-03-29 LT LTEP12714160.4T patent/LT2691155T/lt unknown
- 2012-03-29 HU HUE12714160A patent/HUE041384T2/hu unknown
- 2012-03-29 JP JP2014502803A patent/JP6000329B2/ja active Active
- 2012-03-29 SI SI201231538T patent/SI2691155T1/sl unknown
- 2012-03-29 ES ES12714160T patent/ES2709577T3/es active Active
- 2012-03-29 MX MX2016007829A patent/MX369659B/es unknown
- 2012-03-29 US US13/434,451 patent/US8795673B2/en active Active
- 2012-03-29 CN CN201280016107.4A patent/CN103717262B/zh active Active
- 2012-03-29 NZ NZ726386A patent/NZ726386A/en unknown
- 2012-03-29 EP EP18199729.7A patent/EP3545977A1/en active Pending
- 2012-03-29 KR KR1020227000970A patent/KR20220009505A/ko not_active Application Discontinuation
- 2012-03-29 KR KR1020207010853A patent/KR102272828B1/ko active IP Right Grant
- 2012-03-29 EA EA201991268A patent/EA201991268A3/ru unknown
- 2012-03-29 CN CN201710705089.5A patent/CN107537040A/zh active Pending
- 2012-03-29 EP EP12714160.4A patent/EP2691155B1/en active Active
- 2012-03-29 KR KR1020227028603A patent/KR20220123130A/ko not_active Application Discontinuation
- 2012-03-29 PL PL12714160T patent/PL2691155T3/pl unknown
- 2012-03-29 KR KR1020237029015A patent/KR20230128583A/ko not_active Application Discontinuation
- 2012-03-29 ME MEP-2019-34A patent/ME03353B/me unknown
- 2012-03-29 RS RS20190189A patent/RS58367B1/sr unknown
- 2012-03-29 MX MX2013011215A patent/MX339927B/es active IP Right Grant
- 2012-03-29 UA UAA201312640A patent/UA116524C2/uk unknown
-
2013
- 2013-09-29 IL IL228559A patent/IL228559A/en active IP Right Grant
-
2014
- 2014-06-24 US US14/313,868 patent/US9428543B2/en active Active
-
2016
- 2016-05-03 AU AU2016202832A patent/AU2016202832B2/en active Active
- 2016-07-21 US US15/215,857 patent/US9914748B2/en active Active
- 2016-08-25 ZA ZA2016/05918A patent/ZA201605918B/en unknown
- 2016-08-30 JP JP2016167618A patent/JP6456885B2/ja active Active
-
2017
- 2017-02-22 IL IL250723A patent/IL250723B/en active IP Right Grant
-
2018
- 2018-02-01 US US15/886,495 patent/US10435432B2/en active Active
- 2018-04-25 IL IL258929A patent/IL258929B/en active IP Right Grant
- 2018-08-03 AU AU2018211331A patent/AU2018211331B2/en active Active
- 2018-12-19 JP JP2018236944A patent/JP6797885B2/ja active Active
-
2019
- 2019-02-05 HR HRP20190243TT patent/HRP20190243T1/hr unknown
- 2019-02-07 CY CY20191100166T patent/CY1121321T1/el unknown
-
2020
- 2020-02-11 US US16/787,942 patent/US11090390B2/en active Active
- 2020-08-10 AU AU2020217301A patent/AU2020217301B2/en active Active
- 2020-11-18 JP JP2020191507A patent/JP7269210B2/ja active Active
-
2021
- 2021-07-09 US US17/371,151 patent/US11744900B2/en active Active
-
2023
- 2023-04-21 JP JP2023070124A patent/JP2023083504A/ja active Pending
- 2023-07-14 US US18/352,362 patent/US20240156976A1/en active Pending
-
2024
- 2024-01-09 AU AU2024200123A patent/AU2024200123A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190243T1 (hr) | Priprema konjugata antitijela majtanzinoida postupkom s jednim korakom | |
HRP20190576T1 (hr) | Postupci pripreme konjugata | |
HK1221153A1 (zh) | 抗體-藥物綴合物 | |
HUE053008T2 (hu) | Eljárás antitest-SN-38 CL2A kötõcsoportos immunkonjugátumainak elõállítására | |
IL230719A0 (en) | highly galactosylated antibodies | |
IL228565A0 (en) | A process for preparing conjugates with improved homogeneity | |
ZA201408916B (en) | Novel process for preparation of antibody conjugates and novel antibody conjugates | |
EP2717857A4 (en) | PROCESS FOR SYNTHESIS OF PORPHYRINE-PHOSPHOLIPID CONJUGATES | |
EP2916835A4 (en) | COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE | |
ZA201302986B (en) | Portion capsule for producing a beverage using a portion capsule | |
ZA201307247B (en) | A novel process for preparation of polysaccharides | |
EP2663568A4 (en) | PROCESS FOR THE PREPARATION OF ACETALS | |
WO2012174549A9 (en) | Blockade of eosinophil production by toll-like receptors | |
EP2646431A4 (en) | PROCESS FOR THE PREPARATION OF PAZOPANIB USING A NEW INTERMEDIATE | |
EP2714696A4 (en) | PROCESS FOR PREPARING ANYHYDRUGAL ALCOHOLS | |
PL2681199T3 (pl) | Sposób wytwarzania (-)-hupercyny A | |
EP2776388A4 (en) | AN INEDIC PROCESS FOR THE PREPARATION OF (R) -N-BENZYL-2-ACETAMIDO-3-METHOXYPROPIONAMIDE | |
EP2663569A4 (en) | PROCESS FOR THE PREPARATION OF ALDITOL ACETALES | |
EP2852592A4 (en) | PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE | |
EP2702039A4 (en) | PROCESS FOR THE PREPARATION OF DICYANOCARBOXYLATE DERIVATIVES | |
EP2695938A4 (en) | METHOD FOR PRODUCING ANTIBODIES | |
HK1201063A1 (en) | Process for the preparation of a thioprecursor for statins | |
GB201100283D0 (en) | Novel polymer conjugates and a process for their preparation | |
ZA201401732B (en) | A process for preparation of a tea product | |
GB201210838D0 (en) | Novel process for preparation of antibody conjugates and novel antibody conjugates |